Neuronetics, Inc. (STIM)
After hours:
| Previous close | 3.5200 |
| Open | 3.5200 |
| Bid | 3.4600 x 300 |
| Ask | 3.5300 x 100 |
| Day's range | 3.3450 - 3.5500 |
| 52-week range | 1.0300 - 5.0700 |
| Volume | |
| Avg. volume | 168,998 |
| Market cap | 104.611M |
| Beta (5Y monthly) | 2.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0500 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireNeuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The confere
- GlobeNewswire
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in t
ZacksNeuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
